Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Dubiotech Bets On ''If You Build It, They Will Come,'' Despite Funding Shortages

This article was originally published in PharmAsia News

Executive Summary

Dubai-based biotech research park Dubiotech unveiled plans for what it is calling a "state-of-art nucleotide laboratory complex," hoping it will draw multinational tenants to the Middle East in force

You may also be interested in...



Quintiles Continues Eastward Push, Looks To Russia And Middle East For Growth

The U.S. CRO sees opportunities to align with young, domestic biopharma companies in emerging markets.

Pfizer, Merck Drop Prices For 67 Drugs In UAE; More Reductions Expected

Pfizer Inc. and Merck Sharp & Dohme will reduce prices of 67 drugs in the United Arab Emirates starting July 1, according to the UAE Ministry of Health

Pfizer, Merck Drop Prices For 67 Drugs In UAE; More Reductions Expected

Pfizer Inc. and Merck Sharp & Dohme will reduce prices of 67 drugs in the United Arab Emirates starting July 1, according to the UAE Ministry of Health

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

SC073959

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel